U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053488) titled 'CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection' on June 08.
Brief Summary: This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation. Donor livers will have HLA-A and HLA-B genes knocked out, and HLA class II expression disabled (by targeting the CIITA transactivator gene), aiming to create a "hypoimmunogenic" organ less prone to rejection. The edited liver is then transplanted into patients with end-stage liver disease. The primary focus is on safety and feasibility - determining whether a CRISPR-edited liver can be tr...